Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.

ABSTRACT: We sought to identify the total number of therapeutic trials targeting FLT3-mutant acute myeloid leukemia (AML) to estimate the number of patients needed to satisfy recruitment when compared with the incidence of this mutation in the US AML population. A systematic review of all therapeutic clinical trials focusing on adult FLT3-mutated AML was conducted from 2000 to 2017. An updated search was performed using ClinicalTrials.gov for trials added between October 2017 and December 2018. Analysis was performed for ClinicalTrials.gov search results from 2000 to 2017 to provide descriptive estimates of discrepancies between anticipated clinical trial enrollment using consistently cited rates of adult participation of 1%, 3%, and 5%, as well as 10% participation identified by the American Societ

SUBMITTER: Bucy T 

PROVIDER: S-EPMC6963255 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature